Fixed|Duration Venetoclax plus Obinutuzumab New Standard of ...

Fixed-duration venetoclax plus obinutuzumab improves quality of ...

In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR ( ...

Fixed-duration venetoclax plus obinutuzumab improves quality of ...

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL · Authors.

Fixed-Duration Venetoclax plus Obinutuzumab New Standard of ...

In the phase 3 CLL14 clinical trial, fixed-duration venetoclax plus obinutuzumab was superior to chlorambucil plus obinutuzumab as front-line therapy in ...

Fixed-Duration Targeted Therapy with Venetoclax plus ...

Chicago, IL—In the phase 3 CLL14 trial, fixed-duration therapy with the combination of venetoclax (Venclexta) plus obinutuzumab (Gazyva) was superior to the ...

Fixed-duration venetoclax plus obinutuzumab improves quality of ...

In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR ( ...

Fixed-duration Calquence plus venetoclax, with or without ...

Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic ...

Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with ...

Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st ...

Venetoclax Combined with Obinutuzumab - CLL Society

One-year fixed-duration venetoclax – obinutuzumab (Ven-Obi) is now an established standard treatment for patients with treatment-naive CLL.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ...

Venetoclax–obinutuzumab proved to be effective and to have a low incidence of high-grade toxic effects in patients with relevant coexisting ...

Is Fixed-Duration Therapy the New Standard of Care in Frontline ...

Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal ...

6-year results of the randomized phase 3 CLL14 study | Blood

Key PointsOne-year fixed-duration Ven-Obi results in durable treatment-free remissions, with a 6-year PFS rate of 53% and TTNT rate of 65%, ...

First-line venetoclax combinations versus chemoimmunotherapy in ...

In the venetoclax–obinutuzumab–ibrutinib group, daily ibrutinib (420 mg orally, from day 1 of cycle 1) was added until undetectable MRD was ...

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on ...

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual ...

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves ...

The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease ...

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS With ...

Fixed-duration venetoclax plus obinutuzumab results in high rates of undetectable MRD at the end of treatment, with over 90% of patients ...

The future of fixed-duration therapy in CLL - VJHemOnc

There are a number of studies that explore fixed duration treatment in CLL. The first one being, of course, venetoclax plus obinutuzumab ...

Acalabrutinib Plus Venetoclax and Obinutuzumab Improves CLL ...

The potential approval of fixed-duration acalabrutinib and venetoclax with or without obinutuzumab as a frontline therapy offers the exciting ...

Study Reports Time-Limited Venetoclax-Based Regimens of Benefit ...

In patients who are less fit, however, fixed-duration venetoclax plus obinutuzumab demonstrated superior progression-free survival vs ...

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

The combination of venetoclax plus obinutuzumab or rituximab as first-line therapy has led to a high incidence of undetectable minimal residual ...

Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in ...

Among fit patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration venetoclax plus obinutuzumab (GV), ...